Pluristyx iPSC Partnership | Made Scientific

A single-source path from cell line to commercial supply, pairing Pluristyx’s clinical-grade iPSC platform with Made Scientific’s GMP development and manufacturing.

Integrated iPSC Development & Manufacturing, from Cell Line to Clinic

A single-source model that removes the cost, complexity, and timeline drag of sourcing iPSC starting material

Made Scientific and Pluristyx have partnered to integrate Pluristyx’s clinical-grade iPSC platform, including GMP iPSC lines and derivative cell types such as induced natural killer (iNK) and induced mesenchymal stem (iMSC) cells, directly into Made Scientific’s end-to-end CDMO offering.

Pluristyx serves as Made Scientific’s iPSC and iPSC-derivative supply and development partner, giving clients access to RUO and GMP-ready iPSC lines across R&D, clinical, and commercial manufacturing.

Why it matters: Demand for iPSC-derived cell therapies is accelerating, and the availability and quality of iPSC starting material is one of the biggest variables in timely, cost-effective manufacturing.
What’s different: Pluristyx’s iPSC lines arrive regulatory-ready, so process development and GMP manufacturing can begin on day one.
Where we are: iPSC lines and derivative cell types (iNK, iMSC) are available now through Made Scientific, with built-in safety and immune-evasion features.
What’s next: A coordinated service model for sponsors who plan to further engineer, differentiate, or customize an iPSC bank, enabled by sublicensing of Pluristyx technology through Made Scientific.

“Made Scientific’s development and manufacturing expertise and infrastructure make them an ideal partner to bring the full potential of our iPSC platform to therapeutic developers globally. Together, we’re giving sponsors a coordinated path from clinical-grade starting material through GMP manufacturing, one that’s built for speed, regulatory compliance, and scalability across the cell types that matter most in next-generation autologous and allogeneic programs.”

Priya Baraniak, PhD, Chief Commercial and Development Officer of Pluristyx

How Pluristyx iPSC Technology Fits into Cell Therapy Manufacturing

Initial focus: iPSC-derived programs (iNK, iMSC, and lineage-specific derivatives)

The partnership integrates pre-qualified iPSC starting material directly into existing development and manufacturing workflows, replacing the lengthy upstream work of sourcing, re-characterizing, and licensing iPSC lines with a single operation. In practice, the division is clean: clients leverage Pluristyx for GMP iPSC cell lines and cell engineering services, while Made Scientific provides GMP cell banking and iPSC and iPSC-derivative manufacturing, all in one workflow.

Plug-and-play starting material: pre-qualified, regulatory-ready iPSC lines integrate directly into Made Scientific’s GMP development and manufacturing infrastructure
Single license, single vendor: sublicensing of Pluristyx technology through Made Scientific removes separate license negotiations and multi-vendor qualification
Coordinated differentiation and banking: joint support for cell line differentiation programs and custom GMP master and working cell bank manufacturing

Day-one-ready starting material

Pluristyx iPSC lines arrive with donor consent, characterization, and regulatory documentation already in place, meeting 21 CFR 1271 and 21 CFR 210/211 compliance, so process development and GMP manufacturing can begin immediately rather than after months of qualification.

A compressed path to IND

By avoiding the sourcing and re-characterization of starting material, separate license negotiations, and qualification of multiple vendors, sponsors remove months of timeline and significant program cost with fewer duplicate quality and analytical workstreams.

One point of accountability

Made Scientific and Pluristyx coordinate iPSC sourcing, engineering, differentiation, and GMP banking under a single workflow, removing the handoff risk and delays that typically accompany bespoke iPSC programs.

CDMO execution from concept to clinic

End-to-end process development, technology transfer, GMP master and working cell bank manufacturing, and downstream manufacturing optimized for engineered and differentiated iPSC-derived material and supported by flexible engagement models.

Pluristyx iPSC platform: clinical-grade, regulatory-ready starting material

Proprietary mRNA bulk reprogramming and a polyclonal iPSC approach, producing genetically younger, more stable, and highly expandable cells
Off-the-shelf, clinical-grade RUO and GMP iPSC lines, plus derivative cell types including iNK and iMSC
Built-in safety and immune evasion: FailSafe^® safety switch, iACT™ immune cloaking system, and HLA-null capabilities
Custom gene editing and engineering, supporting both autologous and allogeneic programs

Integrated CDMO services, iPSC-ready by design

GMP cell banking and iPSC and iPSC-derivative (iNK, iMSC) manufacturing, plus development and technology transfer, at Made Scientific
Phase-appropriate quality systems and documentation aligned with FDA, EMA Annex I, and global regulatory requirements (21 CFR 1271, 21 CFR 210/211)
Flexible engagement models spanning RUO feasibility through clinical and commercial supply

RoosterBio

MSC and extracellular vesicle platforms integrated into Made Scientific’s development and manufacturing services, from process development through commercial supply.

Read the announcement

Syenex

RapidCell™ vector technology powers MadeFast™, Made Scientific’s single-step CAR-T platform designed to reduce manufacturing time, cost, and complexity.

Explore the partnership